/PRNewswire/ The "Cardiac Marker Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies,.
Several stocks have undergone significant movements in the recent week. It might be beneficial for investors to have a quick overview of these stocks readily available. Let s take a closer look at.
Roche Holding AG entered into a definitive agreement to buy Lumiradx Ltd.’s point-of-care technology platform for $350 million. The deal is part of Roche’s effort to transform its point-of-care portfolio and enable more patient-centric health care. For Lumiradx, the sale is the end of a journey to restructure and refocus the company and will result in it being delisted from Nasdaq.
BioPharma Credit PLC on Tuesday noted that investee LumiraDx Ltd appointed administrators last week and has since agreed an acquisition deal with Roche Holding AG.
The London-based closed-ended.